GSK plc (GSK)

Executive Summary / Key Takeaways

• GSK's five-year transformation into a focused biopharma company has created a durable growth engine in Specialty Medicines, which delivered 17% constant currency growth in 2025 and now represents over 40% of sales, driving margin expansion and cash generation that supports both R&D investment and shareholder returns.

• The HIV franchise's 10-year head start in long-acting injectables (Cabenuva, Apretude) creates a formidable competitive moat, with these products generating 75% of HIV growth and one-third of U.S. sales, positioning GSK to maintain dominance even as oral competitors emerge.

• While vaccines provide essential cash flow stability, their low single-digit growth outlook and Shingrix's U.S. headwinds reveal the limits of this legacy portfolio, making the specialty transformation essential for sustained outperformance.

• The £40 billion revenue target by 2031, reiterated by incoming CEO Luke Miels, requires execution of 14 pipeline assets with peak sales potential over £2 billion each; the CEO transition adds both fresh perspective and execution risk to this ambitious goal.

• Trading at 14.5x earnings and 17x free cash flow, GSK's valuation appears undemanding relative to specialty pharma peers, suggesting the market has yet to fully price the durability of its HIV moat and the margin expansion potential from its portfolio mix shift.

Setting the Scene: From Conglomerate to Specialty Biopharma

Founded in 1715 and headquartered in Brentford, United Kingdom, GSK's modern incarnation emerged from the 1999 merger of Glaxo Wellcome and SmithKline Beecham. But the story that matters to investors begins in 2021, when the company initiated its most significant strategic shift in two decades: divesting the Consumer Healthcare business to form Haleon plc (HLN) in July 2022 and re-establishing itself as a focused biopharma company. This wasn't a simple portfolio pruning—it was a fundamental reallocation of capital from low-growth consumer brands to high-margin specialty medicines and vaccines.

The significance of this transformation lies in how a company that once sprawled across consumer toothpaste and prescription drugs has delivered 18 consecutive quarters of profitable sales growth since 2021. The strategy concentrates resources on four therapeutic areas where GSK can build durable moats: HIV, respiratory/immunology, oncology, and vaccines. This focus is already bearing fruit: Specialty Medicines grew 17% in 2025 while General Medicines declined 1%, creating a powerful mix shift that lifted gross margins 40 basis points and core operating profit 11% at constant currency.

GSK operates in an industry facing intense pricing pressure, particularly in the United States. Yet the company sits in a structurally advantaged position. The global medicine market is growing 5-8% annually toward $2.4 trillion by 2029, with specialty medicines expanding from 27% of spending in 2014 to 46% by 2029. GSK's pivot toward specialty captures this wave precisely as chronic disease burdens—cancer, respiratory illness, HIV—become the dominant healthcare cost drivers worldwide. The company's £32.7 billion in 2025 sales represent a 7% constant currency increase, outpacing broader pharma market growth and demonstrating that focused innovation can overcome macro headwinds.

Technology, Products, and Strategic Differentiation

The HIV Moat: A Decade of Long-Acting Dominance

GSK's HIV franchise, managed through majority-owned ViiV Healthcare, represents the company's most defensible competitive position. The 2012 acquisition of Shionogi's (SGIOY) interest brought dolutegravir and cabotegravir into the fold, but the real value creation has come from transforming these molecules into long-acting injectable regimens. In 2025, these products generated over 75% of HIV growth and now represent about one-third of U.S. sales, with Cabenuva growing 42% and Apretude for PrEP growing 62%.

GSK has a 10-year head start in long-acting HIV treatment, and management expects to have the only long-acting injectable treatment regimens on the market for many years to come. While competitors develop once-weekly oral alternatives, these are expected to cannibalize daily oral regimens rather than long-acting injectables, preserving GSK's premium positioning. Long-acting therapies command higher prices, create stickier patient relationships, and generate more durable revenue streams than daily pills. With Q6M treatment regimens entering Phase III and filing expected between 2028-2030, GSK is extending its moat just as oral competitors plateau.

The HIV pipeline reinforces this advantage. VH184, a third-generation integrase inhibitor with IP protection through at least 2040, represents the next evolution. The ENTRANCE study for HIV cure/remission, initiated in 2025, offers blue-sky potential. Even without a cure, the base business projects mid- to high single-digit growth through 2026, making it a reliable cash generator that funds riskier R&D elsewhere.

Specialty Medicines: Building the Growth Engine Beyond HIV

While HIV provides the foundation, GSK's broader Specialty Medicines portfolio is where the transformation accelerates. Respiratory, Immunology & Inflammation (RI&I) grew 18% to £3.8 billion in 2025, driven by Benlysta's 22% growth in lupus and Nucala's 15% growth to $2 billion—its 10th consecutive year of double-digit expansion. Nucala's May 2025 FDA approval for COPD opens a massive new market, with management noting it is "very competitive" against Sanofi (SNY) and Regeneron's (REGN) Dupixent, backed by data showing 83% of pulmonologists are motivated to use it.

Oncology, though smaller at £2.0 billion, grew 43% in 2025. Jemperli's 89% growth in endometrial cancer and Ojjaara's 60% growth in myelofibrosis demonstrate early traction. Blenrep, the only anti-BCMA antibody-drug conjugate accessible in community settings where 70% of multiple myeloma patients are treated, achieved approvals in 15 markets and showed a 51% reduction in death risk versus daratumumab in DREAMM-7. Management expects Blenrep to be a material growth driver in the next three to four years, implying a steep revenue ramp that could materially alter the oncology segment's scale.

Specialty medicines carry gross margins 500-1,000 basis points higher than general medicines, so every percentage point of mix shift drives disproportionate profit growth. With specialty targeting over 50% of sales by 2031, GSK is on a path to structurally higher margins. The 14 pipeline assets with peak sales potential over £2 billion each, expected to launch between 2025-2031, provide the growth ammunition. Success in even half of these could add £14 billion in peak sales, making the £40 billion target achievable.

Vaccines: The Stable Foundation with Growth Limits

GSK's £9.2 billion vaccines portfolio grew just 2% in 2025, revealing both its strength and its limitations. Shingrix, the shingles vaccine with >90% efficacy, grew 8% to £3.6 billion, but this masked a critical divergence: strong European and international growth offset U.S. declines. Similarly, Arexvy for RSV grew only 2%, with ex-U.S. gains compensating for U.S. weakness. Bexsero for meningitis grew 16%, but this is a smaller base.

Vaccines provide GSK with three critical advantages: predictable cash flows, manufacturing scale economies, and regulatory expertise that accelerates new product approvals. The 2025 approvals of Penmenvy and Blujepa demonstrate this capability. However, the low single-digit growth outlook for 2026—management expects "low single-digit decline to stable"—means vaccines cannot drive the overall growth narrative. They are the defensive moat that funds the offensive specialty expansion.

The competitive context reinforces this view. Merck's (MRK) Gardasil dominates HPV prevention, and Pfizer's (PFE) Prevnar leads in pneumococcal pediatric vaccines. GSK's Shingrix is best-in-class but faces market saturation in the U.S., where immunization rates in top 10 ex-U.S. markets average only 10%, suggesting international expansion is the growth path. The £1.2 billion U.S. manufacturing investment announced in September 2025 aims to capture this, but the three-year zero tariff agreement with the U.S. provides only temporary protection from trade disruptions.

Financial Performance & Segment Dynamics

Revenue Quality and Mix Shift

GSK's 2025 results show accelerating transformation. Total sales of £32.7 billion grew 7% at constant currency, but the composition reveals the strategic progress. Specialty Medicines' 17% growth added £2.0 billion in incremental revenue, more than offsetting the £100 million decline in General Medicines. This mix shift matters because specialty products carry gross margins of 75-80% versus 60-65% for general medicines. The 40 basis point gross margin improvement in 2025, building to 470 basis points over four years, directly reflects this transition.

The HIV franchise's performance exemplifies pricing power. With 75% of growth from long-acting injectables that command premium pricing, GSK is successfully trading volume for value. Cabenuva's 42% growth and Apretude's 62% growth demonstrate that patients and providers will pay for convenience and efficacy. This supports management's confidence in mid- to high single-digit HIV growth through 2026, even as the broader HIV market matures.

Cash Generation and Capital Allocation

GSK generated £8.9 billion in operating cash flow in 2025, or over £10 billion excluding £1.2 billion in Zantac settlement payments. This represents a £1.6 billion year-on-year increase, driven by higher operating profit and favorable working capital movements. Free cash flow reached £4 billion, or over £5 billion excluding Zantac. This matters because it funds the company's dual priorities: growth investment and shareholder returns.

The company deployed £4.5 billion in CapEx and business development while returning £4 billion through dividends and the £2 billion share buyback program initiated in February 2025. Net debt-to-EBITDA remained stable at 1.3x despite these outflows, demonstrating that GSK can invest for growth without compromising balance sheet strength. The remaining £0.6 billion of the buyback to be completed in H1 2026 signals management's view that the stock remains attractively valued.

R&D investment accelerated 19% to £7.5 billion, reflecting the company's commitment to advancing 58 pipeline assets, including 17 in Phase III. This spending is heavily weighted toward specialty medicines, with five FDA approvals in 2025 and seven new pivotal trial starts. The 11% CER R&D growth expected to continue ahead of sales growth is a strategic choice to feed the 2025-2031 launch cycle.

Margin Expansion and Operating Leverage

Core operating profit grew 11% CER in 2025, 400 basis points faster than sales, demonstrating operating leverage. SG&A expenses grew only 3% as productivity initiatives offset launch investments, while royalty income benefited from the RSV IP settlement and new mRNA streams. The 110 basis point operating margin improvement brought four-year accretion to 470 basis points, primarily driven by the portfolio transition toward specialty medicines.

This margin expansion shows GSK can grow profitably without sacrificing R&D investment. Unlike peers where margin pressure from patent cliffs has compressed profitability, GSK's focused portfolio generates higher returns on incremental investment. The 29.9% reported operating margin for 2025 positions GSK competitively against Sanofi's 14.3% and toward AstraZeneca's (AZN) 21.6%.

Outlook, Management Guidance, and Execution Risk

The £40 Billion Question

Management's reiterated confidence in achieving "more than £40 billion" in revenue by 2031 is the central valuation hinge. Luke Miels, who took over as CEO on January 1, 2026, stands behind the target, noting that the majority of the products in the forecast were identified during his tenure as commercial lead. Success requires adding £8 billion in revenue over six years, implying a 5-6% CAGR on top of the current 7% growth rate.

The pathway involves three components: maximizing new product launches, accelerating late-stage pipeline assets, and strategic business development. The 2025-2026 acquisition spree—Aiolos Bio, Elsie Biotechnologies, Cellphenomics, IDRx, RAPT Therapeutics, and 35Pharma—shows management deploying capital to fill pipeline gaps, particularly in oncology and immunology. These deals signal a strategy to acquire assets in areas where GSK seeks to bolster its competitive standing.

2026 Guidance and Phasing Dynamics

For 2026, management guides to 3-5% sales growth, 7-9% core operating profit and EPS growth, and a 70p dividend (6% increase). Operating profit growth will be heavily weighted towards the second half, reflecting £300 million in Q4 2025 charges and the annualization of the RSV settlement in Q2. This creates a potential setup for guidance beats in H2 2026 as comparatives ease.

Specialty Medicines are expected to grow low double-digit, with HIV mid- to high single-digit, while Vaccines and General Medicines both face low single-digit decline to stable outlooks. This divergence reinforces the portfolio shift thesis: GSK is becoming a specialty medicines company. The 6% dividend increase, supported by strong cash generation, provides income investors a floor while the growth story plays out.

The Dolutegravir Patent Cliff

A critical risk is the 2029-2030 loss of exclusivity for dolutegravir, GSK's blockbuster HIV integrase inhibitor. While this will create a temporary dip in the HIV franchise, the company expects long-acting injectables and VH184 to drive a return to growth. This tests the durability of the HIV moat: if GSK can maintain franchise value through patent expiry, it validates the platform's strength.

Risks and Asymmetries

Competitive Pressure in High-Growth Areas

GSK's limited oncology depth compared to Merck's Keytruda dominance and AstraZeneca's precision medicine pipeline represents a strategic vulnerability. While Jemperli and Blenrep show promise, GSK lacks a true oncology blockbuster. Oncology offers high margins and fast growth; if the 14 pipeline assets fail to deliver major oncology wins, GSK will remain a secondary player in this segment.

The competitive threat extends to respiratory/immunology. While Nucala's COPD approval positions it against Dupixent, Sanofi's immunology franchise is larger. GSK's strategy of competing on data—emphasizing hospitalization reductions—must overcome Dupixent's established market presence. Failure to capture meaningful COPD share would limit RI&I growth to mid-single digits.

US Pricing and Regulatory Risk

The December 2025 agreement with the US Administration on drug pricing and albuterol reserves signals heightened government scrutiny. Approximately 30-40% of GSK's revenue comes from the U.S., and Medicare Part D redesign already impacts the HIV portfolio. If pricing reforms accelerate beyond current assumptions, specialty medicine margins could compress, undermining the core thesis.

The three-year zero tariff agreement on UK-manufactured pharmaceuticals provides temporary relief. With £1.2 billion invested in U.S. manufacturing, supply chain disruption from trade policy changes could raise COGS and delay launches, impacting both growth and margins.

Execution Risk Under New Leadership

Emma Walmsley's departure introduces execution risk. Luke Miels inherits a company at an inflection point. While his commercial expertise aligns with the launch-heavy 2025-2031 period, the £40 billion target requires flawless R&D execution. Management transitions often lead to strategic shifts or execution missteps during critical growth phases. If Miels adjusts the 2031 target or fails to deliver on pipeline promises, investor confidence could wane.

Valuation Context

Trading at $54.04 per share, GSK's valuation metrics reveal a disconnect between execution and market perception. The 14.5x trailing P/E and 17.0x price-to-free-cash-flow ratios compare favorably to peers: AstraZeneca trades at 28.1x earnings, Pfizer at 20.3x, Merck at 16.3x, and Sanofi at 19.9x. Even relative to its own growth rate, the P/E appears undemanding.

The EV/EBITDA multiple of 8.4x sits below the pharma average of 10-12x, suggesting the market assigns a conglomerate discount despite the specialty transformation. This implies upside if GSK successfully executes its 2031 target. A specialty-focused pharma with 50% of sales from high-growth, high-margin medicines typically commands a premium multiple. If GSK reaches £40 billion revenue with specialty representing over 50%, a re-rating to 18-20x earnings would imply 25-35% upside from current levels.

The 3.26% dividend yield provides downside protection, with a 46.5% payout ratio indicating sustainability. The £2 billion buyback program signals management's confidence and provides technical support. Net debt-to-EBITDA of 1.3x offers balance sheet flexibility for acquisitions or increased returns if cash generation continues exceeding £10 billion annually.

Conclusion

GSK's transformation from diversified pharma to specialty medicines leader is delivering 17% growth in the core franchise, expanding margins, and generating robust cash flow. The HIV long-acting injectable moat provides a decade of defensible, high-margin revenue that funds R&D across oncology and immunology. While vaccines offer stability, the specialty mix shift is the true value driver, positioning GSK for structurally higher profitability.

The investment thesis hinges on execution of the £40 billion 2031 target under new CEO Luke Miels and successful navigation of the dolutegravir patent cliff. At 14.5x earnings, the market prices GSK as a low-growth pharma when it is delivering mid-single-digit sales growth with accelerating operating leverage. If Miels maintains momentum and the pipeline delivers major oncology wins, GSK will deserve a specialty pharma multiple, offering 25%+ upside. The downside is protected by the vaccine cash flow, HIV moat, and 3.3% yield.